This press release today about BTI's research deal with MedImmune adds more confirmation that the pharmaceutical companies take BTI very seriously. Investors should note that when Shire, Abbott and MedImmune (AstraZeneca) make research deals, they don't do it without taking a pretty good peak into the technology and then judging it worthy of their time and money.

.

Investors might want to take note of that. They should also take note that so much time has passed with the Shire project that we have no choice but to assume that the work was a success and that Shire and BTI are trying to figure out what to do about that. Then there's Abbott. Who knows where they're at. 

.

And those Texas mice ain't talkin'. I say sweat 'em unless they're already on the night train to the big adios, in which case we need the coroners' report.